Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen

Clin Infect Dis. 2003 Oct 1;37(7):e109-11. doi: 10.1086/377609. Epub 2003 Sep 5.

Abstract

We describe an adult woman infected with human immunodeficiency virus type 1 (HIV-1) who developed dilated cardiomyopathy (DCM) with histologically confirmed mitochondrial damage while receiving anti-HIV-1 combination therapy that included nelfinavir, lamivudine, and zidovudine. DCM resolved after discontinuation of the regimen, and cardiac function remained normal after initiation of treatment with nelfinavir, lamivudine, and abacavir, which indicates that DCM was induced by mitochondrial toxicity, most likely caused by zidovudine.

MeSH terms

  • Adult
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Cardiomyopathy, Dilated / chemically induced*
  • Female
  • HIV Infections / drug therapy
  • HIV-1 / drug effects
  • Humans
  • Zidovudine / adverse effects*

Substances

  • Anti-HIV Agents
  • Zidovudine